Predicting Response and Recognizing Resistance: Improving Outcomes in Patients with Castration-Resistant Prostate Cancer

Optimal sequencing strategies for approved agents in metastatic castration-resistant prostate cancer (mCRPC) are unclear. Retrospective clinical studies suggest cross-resistance between specific therapies. This review assesses treatment decisions for mCRPC. Increased use of chemohormonal therapy in castration-sensitive disease may affect subsequent treatment decisions in mCRPC. Initial abiraterone or enzalutamide treatment may result in cross-resistance for subsequent AR-targeted therapy. Clinical responses may be seen in both docetaxel- and cabazitaxel-treated patients progressing after treatment with abiraterone or enzalutamide. These observations are supported by proposed resistance mechanisms. In conclusion, small, retrospective studies suggest cross-resistance between specific therapies in mCRPC. Larger prospective studies are required.

Urology. 2017 Aug 07 [Epub ahead of print]

Neal Shore, Axel Heidenreich, Fred Saad

Carolina Urologic Research Center, Myrtle Beach, SC. Electronic address: ., University of Cologne, Cologne, Germany., Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.